1. Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8
Charlène Coquil, Alessandra Boletta, Pamela V Tran, Michal Mrug, Marco Pontoglio, Melanie Grosch, Nathalie Desban, Benoit Villiers, Evelyne Fischer, Katy Billot, Thomas Weimbs, Darren Wallace, Béatrice Josselin-Foll, Claire Delehouzé, Laurent Meijer, Nikolay Bukanov, Oxana Ibraghimov-Beskrovnaya, Ralph Witzgall, Sophie Saunier, Nassima Oumata, Alain Fautrel, Marie Trudel, Yannick Le Meur Am J Physiol Renal Physiol . 2018 Jul 1;315(1):F57-F73. doi: 10.1152/ajprenal.00489.2017.
Following the discovery of (R)-roscovitine's beneficial effects in three polycystic kidney disease (PKD) mouse models, cyclin-dependent kinases (CDKs) inhibitors have been investigated as potential treatments. We have used various affinity chromatography approaches to identify the molecular targets of roscovitine and its more potent analog (S)-CR8 in human and murine polycystic kidneys. These methods revealed casein kinases 1 (CK1) as additional targets of the two drugs. CK1ε expression at the mRNA and protein levels is enhanced in polycystic kidneys of 11 different PKD mouse models as well as in human polycystic kidneys. A shift in the pattern of CK1α isoforms is observed in all PKD mouse models. Furthermore, the catalytic activities of both CK1ε and CK1α are increased in mouse polycystic kidneys. Inhibition of CK1ε and CK1α may thus contribute to the long-lasting attenuating effects of roscovitine and (S)-CR8 on cyst development. CDKs and CK1s may constitute a dual therapeutic target to develop kinase inhibitory PKD drug candidates.
2. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells
N Mouchet, J Lahti, N Desban, K Godl, D Twitchell, H Galons, T I Roumeliotis, N Loaëc, M-D Galibert, C Bruyère, C Delehouzé, L Meijer, N Oumata, J Grenet, S D Garbis, E G Giannopoulou Oncogene . 2014 Dec 11;33(50):5675-87. doi: 10.1038/onc.2013.513.
To understand the mechanisms of action of (R)-roscovitine and (S)-CR8, two related pharmacological inhibitors of cyclin-dependent kinases (CDKs), we applied a variety of '-omics' techniques to the human neuroblastoma SH-SY5Y and IMR32 cell lines: (1) kinase interaction assays, (2) affinity competition on immobilized broad-spectrum kinase inhibitors, (3) affinity chromatography on immobilized (R)-roscovitine and (S)-CR8, (4) whole genome transcriptomics analysis and specific quantitative PCR studies, (5) global quantitative proteomics approach and western blot analysis of selected proteins. Altogether, the results show that the major direct targets of these two molecules belong to the CDKs (1,2,5,7,9,12), DYRKs, CLKs and CK1s families. By inhibiting CDK7, CDK9 and CDK12, these inhibitors transiently reduce RNA polymerase 2 activity, which results in downregulation of a large set of genes. Global transcriptomics and proteomics analysis converge to a central role of MYC transcription factors downregulation. Indeed, CDK inhibitors trigger rapid and massive downregulation of MYCN expression in MYCN-amplified neuroblastoma cells as well as in nude mice xenografted IMR32 cells. Inhibition of casein kinase 1 may also contribute to the antitumoral activity of (R)-roscovitine and (S)-CR8. This dual mechanism of action may be crucial in the use of these kinase inhibitors for the treatment of MYC-dependent cancers, in particular neuroblastoma where MYCN amplification is a strong predictor factor for high-risk disease.
3. Modeling of Dynamic Recrystallization Evolution for Cr8 Alloy Steel and Its Application in FEM
Xuewen Chen, Jiawei Sun, Bingqi Liu, Tao Huang, Bo Zhang, Xudong Zhou, Danqing Yin, Zhen Yang Materials (Basel) . 2022 Oct 1;15(19):6830. doi: 10.3390/ma15196830.
In the process of Cr8 roller production, the phenomenon of coarse grain size and uneven grain size often appears, which makes the mechanical properties of the material decrease sharply. Accurate dynamic recrystallization model is the basis for predicting the change of grain size during thermal processing, and is an important basis for refining grain and improving material properties. In this study, the isothermal compression experiment was carried out on Cr8 alloy steel at 900-1200 °C and 0.005-0.1 s-1by Gleeble -1500D thermal simulation compressor, and the stress dates of Cr8 alloy steel were obtained. According to experimental data, the Kopp dynamic recrystallization model of Cr8 alloy steel was established. The dynamic recrystallization volume fraction obtained by Kopp model was compared with that obtained by experiment at the same temperature and strain rate. The correlation value was 0.988, and the root mean square error (RMSE) was 0.053, which proved that the DRX model established was reliable. Through the secondary development of the program, the DRX model of Cr8 alloy steel was written into the software Forge®to verify the microstructure evolution model. The compression process of a cylindrical specimen of Cr8 alloy steel at 0.1 s-1and 1050 °C was simulated, and the DRX microstructure evolution of the alloy was calculated. The comparison between the final grain size calculation results and the test metallographic photos of samples in different deformation zones shows the relative error of the grain size was less than 10.6%, indicating that the DRX model of Cr8 alloy steel can better predict the dynamic recrystallization of Cr8 alloy steel.
CAS No.: 1786438-30-9
Purity: ≥99% (HPLC)
